# Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial

> **NCT01160926** · PHASE1 · TERMINATED · sponsor: **The Christie NHS Foundation Trust** · enrollment: 31 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** AZD6244
- **DRUG:** Cediranib (AZD2171)

## Key facts

- **NCT ID:** NCT01160926
- **Lead sponsor:** The Christie NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2013-10
- **Final completion:** 2016-11-04
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** 2 DLTs had been reported from first 4 patients on lowest possible dose cohort.
- **Last updated:** 2023-04-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160926, "Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01160926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*